Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Leukemia × revumenib × Clear all

Status

No longer available 1

Sponsor Class

Study Type

Interventional 6 Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1 Leukemia 1

Interventions

fludarabine phosphate 2 revumenib 1 midostaurin 1 immunotoxin HA22 1 glucarpidase 1 fludarabine 1 Whole-Body Irradiation 1 Tacrolimus 1 Mycophenolic Acid 1 HA 22 1 Cytarabine 1 Cyclophosphamide 1 Cord Blood Stem Cell Transplantation 1 Carboxypeptidases 1 Busulfan 1 Bone Marrow Transplantation 1 AP 1903 reagent 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡